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Scientiﬁc Article

Expanding the Utilization of Rectal Spacer
Hydrogel for Larger Prostate Glands (>80 cc):
Feasibility and Dosimetric Outcomes
Marcio Fagundes, MD,* Maria Amelia Rodrigues, MD, Steve Olszewski, MD,
Fazal Khan, CMD, Craig McKenzie, CMD, Alonso Gutierrez, PhD,
Michael Chuong, MD, and Minesh Mehta, MD
Radiation Oncology Department, Miami Cancer Institute, Miami, Florida
Received 3 August 2020; accepted 5 January 2021
Purpose: The Hydrogel Spacer Prospective Randomized Pivotal Trial achieved mean rectoprostatic spacing of 12.6 mm resulting in
lowering of rectal V70 from 12.4% (without spacer) to 3.3% (with spacer) in patients with glands up to 80 cm3. The value of this
approach in patients with larger glands is inadequately established. This study assesses the feasibility and dosimetric outcomes of
perirectal spacing in patients with prostate cancer with larger glands (>80 cm3).
Methods and Materials: Between January 2017 and December 2019, 33 patients with prostate glands >80 cm3 (mean 108.1 cm3; range,
81.1-186.6 cm3) were treated, 15 with glands >80 to 100 cm3 and 18 >100 cm3. Median follow-up was 10 months (range, 3-26). The
median international prostate symptom score was 9 (range, 1-18). Hydrogel was placed under local anesthesia in all cases. Treatment
modality included intensity modulated radiation therapy in 15 and proton therapy (PT) in 18 patients. Treatment targeted the prostate
plus seminal vesicles in 21 patients and 12 also had elective nodal irradiation. Conventional fractionation (CF) to 78 Gy in 39 fractions
was used in 16 and moderate hypofractionation (HF) to 70 Gy in 28 fractions in 17 patients.
Results: In the CF group, mean rectum (r) V75, 70, 60, 50 was 0.87%, 2.25%, 5.61%, and 10.5%, respectively. For glands >80 to 100
cm3 and >100 cm3, rV70 was 2.55% and 2%, respectively. In HF patients, mean rV65, 63, 60, and 50 was 1.67%, 2.3%, 3.4%, and
8.6%. For glands >80 to 100 cm3 and >100 cm3, rV63 was 2% and 2.56%, respectively. Overall, the mean midgland rectoprostatic
hydrogel separation was 9.3 mm (range, 4.7-19.4 mm). All patients tolerated treatment well; no acute grade 2 or higher adverse
gastrointestinal events were observed.
Conclusions: Hydrogel placement is feasible in prostate glands larger than 80 cm3 with favorable dosimetric outcomes.
Ó 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
External beam radiation therapy (EBRT) is commonly
used in the curative treatment of localized prostate cancer.
Despite advances in image guided treatment delivery with
increasing tumor targeting precision, the rectum remains
an organ at risk for radiation-induced toxicity.1-9
Both prospective multi-institutional studies10-12 and
retrospective studies demonstrated the feasibility of rectal
spacer application to improve rectal sparing and mitigate
rectal toxicity, but essentially all of these have limited the
use of the spacer to glands <80 cm3.13-17
The SpaceOAR System (Augmenix, Inc, Waltham,
MA) is a slowly absorbable hydrogel injected into
Denonvillier's space, which temporarily displaces the
rectum away from the prostate and thus decreases rectal
dose. The SpaceOAR Pivotal Trial11 compared patients
receiving EBRT treated with or without rectal spacer.
Postspacer plans signiﬁcantly reduced mean rV70 (12.4%
to 3.3%, P < .0001) with a reduction in rectal toxicity.11
To date, there remains a scarcity of published data on
the feasibility, outcomes, and technical aspects pertaining
to hydrogel application in patients with larger glands. The
present study reports on the feasibility and dosimetric
outcomes of patients with large prostate glands (>80 cm3)
with a subset larger than 100 cm3, treated with conventional as well as moderately hypofractionated EBRT and
rectal spacer.

Methods and Materials
Between January 2017 and December 2019, 33 patients with localized prostate cancer with gland volume
exceeding 80 cm3 (median 101.2 cm3; range, 81.1-186.6
cm3) received deﬁnitive EBRT with curative intent.
Fifteen patients had glands >80 to 100 cm3 and 18 had
glands >100 cm3. The median international prostate
symptom score was 9 (range, 1-18) with a mean value of
8.8. Median patient age was 73 years (range, 59-83).
Median follow-up was 10 months (range, 3-26 months).
The mean interval from hydrogel injection to computed
tomography (CT) simulation was 1.6 days (range, 1-5).
Planning magnetic resonance imaging (MRI) for image
fusion was obtained after the CT simulation on same day,
consisting of axial T1, fat suppression T2, and sagittal T2
sequences. Fused MRI was used to assist in target contouring and hydrogel delineation. Rectoprostatic hydrogel
separation was ﬁrst measured at midgland, deﬁned as half
distance between base and apex along prostate sagittal
midline. Additional measurements were performed at 1
and 2 cm cephalad and caudad of midgland along
midline.
There were no hydrogel procedure-related complications. During treatment, patients were assessed weekly
toxicities were recorded using Common Terminology
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Criteria for Adverse Events, version 4.0 (available online
at https://doi.org/10.1016/j.ijrobp.2020.01.026). After
completion of treatment, patients were seen in follow-up
at 3-month and subsequently at 6-month intervals.
Pretreatment patient characteristics are displayed in
(Table 1). No patients had extraprostatic disease extension. Before hydrogel placement, 11 patients (33.3%)
were on aspirin and another 4 (12.1%) were either on
Plavix or Eliquis. Patients on aspirin or Plavix held the
medication 7 days before the procedure and Eliquis was
held 2 days prior; all resumed medication within 24 hours
after hydrogel placement. This retrospective review was
approved Baptist Health South Florida Institutional Review Board.

Hydrogel procedure
All procedures were performed under local anesthesia.
Bowel preparation included a ﬂeet enema 3 to 4 hours
before the procedure. One hour before the procedure,
Emla topical anesthetic (lidocaine/prilocaine cream) was
applied on the perineum and patients were given oral
premedication consisting of a single dose of prophylactic
antibiotic consisting of cefadroxil 500 mg by mouth.
Patients with history of allergy to penicillin or cephalosporin were given a single dose of Bactrim DS. In addition, oral premedication for pain consisted of
acetaminophen 500 mg single dose given with antibiotics
in 24 of 33 patients (72.7%). Nine patients received
hydrocodone/acetaminophen 5 to 300 mg single dose.
Patients were asked to empty their bladder just before the
procedure.
Interstitial numbing was performed using mixed 2%
plain lidocaine buffered with sodium bicarbonate 8.4%
solution in a 20-mL syringe in a ratio of 10:1. Numbing
was performed along the midline, corresponding to the
path of the hydrogel needle and up against the capsule of
the prostate apex on both sides using a median total
volume of 10 cm3 (range, 10-18 cm3). After transperineal
ﬁducial marker placement, the hydrogel needle was
inserted.
The hydrogel application technique has been described
by Hatiboglu et al.12 We describe additional steps used at
our institution to optimize hydrogel placement, particularly useful in larger glands, which include (1) maximize
anatomic delineation, (2) steps to optimize needle placement, (3) and hydrogel dissipation during injection.
Maximize anatomic delineation
Because large glands tend to compress the rectoprostatic space (Figs 1A-B), it is important to lower the probe
to increase the prostate-rectum separation to improve
hydrogel needle access. On lowering the probe, air artifact
may develop obscuring the ultrasound image. In the case
shown, artifact was located at the apex entrance level
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Table 1

Patient characteristics

Characteristics

n (%)

Mean age (y)
Mean follow up (mo)
Prostate size
>80-100 cm3
>100 cm3
IPSS score
Mean (range)
Median
PSA
<10
10-20
>20
Stage
T1c
T2a
T2b
T2c
Gleason score
6
7 (3 þ 4)
7 (4 þ 3)
8 (4 þ 4)
9 (4 þ 5)
NCCN risk group
LR
IR
HR
Dose regimen
CF 78 Gy/39 fractions
HF 70 Gy/28 fractions
Radiation therapy modality
IMRT
Proton
ADT (duration)
LR
IR (6 mo)
HR (18 mo)
Hydrogel procedure
Local anesthesia
Aspirin
Anticoagulants
History of hemorrhoid surgery
History of Transurethral procedure
HoLEP
MRI staging
Negative capsule
invasion or extraprostatic extension

73 (59-83)
10.7 (3-26)
15 (45.4%)
18 (54.6%)
8.8 (1-18)
9
20 (60.6%)
10 (30.3%)
3 (9.1%)
23 (69.7%)
4 (12.1%)
4 (12.1%)
2 (6.1%)
5 (15.2%)
13 (39.4%)
7 (21.2%)
7 (21.2%%)
1 (3%)
4 (12.1%)
19 (57.6%)
10 (30.3%)
16 (48.4%)
17 (51.6%)
15 (45.4%)
18 (54.6%)
0/4
7/19
10/10
33 (100%)
11/33 (33.3%)
4 /33 (12.1%)
4 /33 (12.1%)
1/33 (3%)
33 (100%)
33 (100%)

Abbreviations: ADT Z androgen deprivation therapy; CF Z conventional fractionation; HF Z moderate hypofractionation; HoLEP
Z Holmium laser enucleation of prostate; HR Z high risk; IMRT Z
intensity modulate radiation therapy; IPSS Z international prostate
symptom score; IR Z intermediate risk; LR Z low risk; MRI Z
magnetic resonance imaging; NCCN Z National Comprehensive
Cancer Network; PSA Z prostate-speciﬁc antigen.

(Fig 1C). An ultrasound probe standoff saline balloon can
be employed to mitigate artifact and improve anatomic
delineation (Fig 1D).
Steps to optimize needle placement
On sagittal view, the needle is introduced and
advanced up to midgland avoiding the rectal wall (Figs
2A-C). Hydrodissection is initiated with a small puff of
saline (0.5-1 cm3) injected ﬁrst in the sagittal plane to
conﬁrm that rectoprostatic space opens (Fig 2D).
The ultrasound is then switched to axial plane and
probe is moved caudally, such that the needle tip is
visualized. Next, the needle tip is slowly and gently
wiggled approximately 2 mm back and forth in the
anteroposterior direction to make sure the needle is not
catching or “dragging” the outer layers of the rectal wall
or the rectoprostatic fascia. Another puff (0.5-1 cm3) is
injected on axial plane to visualize the actual right-to-left
symmetry of saline dissipation (Fig 2E). We also evaluate
whether the rectoprostatic space is clearly opening
resulting in a dark “water” ultrasound signal and at the
same time displacing the rectal wall (Fig 2E). Saline
permeation into the rectal wall would be suggested by a
gray ultrasound signal blurring the rectal wall. Hydrodissection is then completed on sagittal view with a total
volume rarely exceeding 6 cm3.
Whenever saline distribution is asymmetrical, despite
having needle at midline, we consider adjusting the needle laterally by 5 to 10 mm to the side with less saline to
correct the asymmetry. Such adjustment requires pulling
the needle back to just above apex and readvancing it to
the intended side. This maneuver should be performed on
the sagittal plane only to ensure that the needle does not
drop toward the rectum or rise toward the prostate fascia,
with the needle tip always in view.
Hydrogel dissipation during injection
To maximize hydrogel dissipation from base to apex,
especially in the larger glands, we start the hydrogel injection 1 cm cephalad of midgland and perform a cephalocaudad needle pull back during continuous injection to
just caudad of midgland (Figs 3A-C). When needle pull
back is employed during injection, caution must be
exercised to avoid over injection at the apex or caudal of
the prostate.

Applicability of standoff saline balloon
We typically use a condom to cover the ultrasound probe.
An ultrasound standoff saline balloon is useful in selected
instances when there is artifact created by gas obscuring the
image, which cannot be cleared by raising the probe anteriorly
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Figure 1 (A-B) Axial and sagittal views of large gland (186.6 cm3) illustrate a tight rectoprostatic space. (C) Sagittal view of 186.6
cm3 gland demonstrates air artifact obscuring anatomy at crucial needle entrance into rectoprostatic space at the apex. Dashed white line
demarcates the intended hydrogel needle path. (D) Sagittal view of the gland with standoff saline balloon which mitigates air artifact;
pertinent structures abutting rectoprostatic space are illustrated: rectoprostatic space (yellow), rectal wall and underlying mucosa (red),
saline balloon (blue), ultrasound probe surface (white), and needle landing zone (green circle). (A color version of this ﬁgure is available
at https://doi.org/10.1016/j.adro.2021.100651.)

Figure 2 (A) Sagittal view illustrates needle approaching rectoprostatic space entrance point at apex. Needle will be angled posteriorly
after passing rectal hump such to avoid transecting rectal wall at this point. (B) Needle entering rectoprostatic space at apex. (C) Needle
in rectoprostatic space approaching midgland. Needle must be kept off rectal wall as it advances. (D) Hydrodissection opens rectoprostatic space. (E) Axial plane veriﬁcation illustrates needle at midline, in free space, off rectal wall, with good symmetry of saline
dissipation.
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Figure 3

(A) Hydrogel injection (needle just cephalad of midgland); (B) needle at midgland; and (C) needle just caudal of midgland.

against the prostate or when raising the probe would result in
signiﬁcant narrowing of the rectoprostatic space. The largest
gland we treated in this series, measuring 186.6 cm3, is
illustrated in Figure 1A-B. There were 2 reasons to use a
standoff balloon in this case. First, there was air artifact
obscuring the critical needle entrance point at the apex (Fig
1C). The balloon cleared the air artifact providing visibility
of the rectal wall and fascia at the apex (Fig 1D). Second, the
balloon improved the deﬁnition of the rectal mucosa and wall,
providing even more conﬁdence in the needle tip position and
ability to avoid penetration of the rectal wall during needle
insertion, a crucial concern in cases with very tight rectoprostatic space (Figs 1D, 2A-C). The ﬁll volume of the balloon
must be kept to a minimum (4-5 cm3), enough to improve
rectal wall visibility. After hydrodissection begins, the saline
balloon should be completely deﬂated to eliminate any volume that would impede hydrogel separation (Figs 3A-C).

Simulation
Bowel preparation included ﬂeet enema 3 to 5 hours
before CT scan. Patient we also asked to maintain looser
stools with the aid of stool softeners and low gas diet.
Before CT and MRI, patients were instructed to empty
their bladder and drink 24 ounces of water, seeking to
achieve a “comfortable bladder ﬁll” of 250 to 350 cm3.
Mean interval between hydrogel placement and simulation was 1.6 days (range, 1-5 days).

Target deﬁnition and dose regimens
Intensity modulated radiation therapy (IMRT) planning and delivery used volumetric arc therapy technique.
Proton therapy employed pencil beam scanning technique
delivered with lateral opposed ﬁelds. Prostate clinical
target volume (CTV) was deﬁned on CT after MRI
fusion. CTV to planning target volume (PTV) expansions
were 4 mm posteriorly and 6 mm elsewhere.
In low-risk patients, the CTV included the prostate þ
proximal seminal vesicles (1 cm cephalad from origin and
1 cm left and right of midline) deﬁned as (prostate CTV þ

SVprox). In intermediate-risk patients, 2 CTV and PTV
volumes were created; the smaller volume deﬁned as
(PTV_P þ SVprox) received the full prescription dose
and a larger volume including the entire seminal vesicles
received a minimum of 54 to 56 Gy. For those treated
with conventional fractionation (CF) to 78 Gy in 39
fractions, the ﬁrst phase targeted the (PTV_P þ SV) to 54
Gy in 27 fractions, followed by a boost to the (PTV_P þ
SVprox) to 78 Gy. In patients treated hypofractionation
(HF) to 70 Gy in 28 fractions, we used a simultaneously
integrated boost approach where (PTV_P þ SVprox)
received 2.5 Gy per fraction to 70 Gy and the distal
seminal vesicle received 56 Gy in 2 Gy per fraction.
High-risk patients were treated with 78 Gy in 39
fractions in 2 phases: the high-dose volume (PTV_P þ
SVprox) received 24 Gy in 12 fractions. The second
phase used a simultaneously integrated boost approach
targeting the (PTV_P þ SV) prostate þ seminal vesicles
to 54 Gy in 27 fractions and pelvic nodes received 48.6
Gy in 1.8 Gy fractions. Pelvic nodes included obturator,
iliac, presacral and common iliac nodes to L4 to L5
junction.

Risk groups and treatment delivered
Of the 33 patients, 4 were low risk (12.1%), 19 intermediate risk (57.5%), and 10 high risk (30.3%). All 4
low-risk patients were treated to 70 Gy in 28 fractions, 2
with IMRT and the other 2 with proton therapy. Of the 19
intermediate-risk patients, 2 patients (10.5%) met the
minimum threshold risk of 15% for lymph node metastasis and received elective pelvic lymph treatment performed in conventional fractionation. Lymph node risk
was estimated using the Memorial Sloan Kettering Cancer Center pelvic lymph node nomogram and Briganti
nomograms.18,19 The remaining 17 patients treated to
prostate þ seminal vesicles, 6 (31.6%) with HF and 13
(68.4%) with CF. Ten of 33 patients (30.3%) had highrisk disease, all of whom were treated to 78 Gy in 39
fractions with a minimum dose of 48.6 Gy to elective
pelvic lymph nodes. Overall, 12 patients were treated to
prostate, seminal vesicles, and pelvic nodes.

6

M. Fagundes et al

Advances in Radiation Oncology: MaydJune 2021

Table 2 Mean and median rectoprostatic hydrogel separation (mm)
Prostate size

>80-100 cm3

All

>100 cm3

Sagittal midline Mean Median Mean Median Mean Median
separation
Cephalad 2 cm 7.8 8.0
Cephalad 1 cm 10.1 9.9
Midgland
9.3 8.9
Caudad 1 cm
8.6 8.6
Caudad 2 cm
5.9 6.3

11.9 8.4
10.8 11.2
10.5 9.9
7.6 9
6.7 6.8

7.6
9.6
8.3
8
5.3

8.0
9.7
8.3
8.2
5.6

Dietary recommendations during treatment
Patients were routinely instructed to maintain loose
stools with the aid of over-the-counter stool softeners and
to follow a low-gas-producing diet. This recommendation
was derived from early observations using rectal spacer
where rectal distension during treatment by either constipation or gas was correlated with increased rectal
dose.20
For IMRT patients, setup used cone beam computed
tomography for all fractions. For proton patients, cone
beam computerized tomography was performed on ﬁrst
treatment and then weekly thereafter, and 2 orthogonal xrays were obtained daily to conﬁrm all ﬁducials were
within the 2 mm tolerance expansion.21

Results
Overall, the mean midgland rectoprostatic hydrogel
separation along the anterior to posterior axis was 9.3 mm
(4.7-19.4 mm). The separation was 9.9 mm (range, 6.619.4 mm) for glands measuring >80 to 100 cm3 and 8.8
mm (range, 4.7-12.3) for glands >100 cm3.
Rectoprostatic hydrogel separation was also measured
1 and 2 cm both cephalad and caudad from the midgland
along the sagittal plane. The mean cephalad 1 and 2 cm
separation was 10.1 and 7.8 mm and the caudad 1 and 2

cm separation was 8.6 and 5.9 mm, respectively. Table 2
displays the corresponding values for patients with glands
>80 to 100 cm3 and >100 cm3.
In patients treated with CF, the mean rV70 was 2.55%
(range, 0.73-4.7) and 2% (range, 0.3-3.0) for glands >80
to 100 cm3 and >100 cm3, respectively (Table 3). In
patients treated with HF, the rV63 was 2% (range, 0.176.7) and 2.56% (range, 0.16-5.8), for glands >80 to 100
cm3 and >100 cm3.
In the CF group, the overall mean rV75, 70, 60, and 50
were 0.84%, 2.25%, 5.61%, and 10.5%, respectively. In
patients for whom treatment included elective pelvic
lymph nodes, the mean rV75, 70, 60, and 50 were 0.87%,
2.3%, 5.66%, and 10.7%, respectively (Table 4). In the
moderately HF group, the overall mean rV65, 63, 60, and
50 were 1.67%, 2.3%, 3.4%, and 8.6%, respectively
(Table 4).
Bladder and penile bulb dosimetry were also tracked.
With respect to bladder dosimetric outcomes in the CF
group, mean bladder (b) V70, 60, and 50 were 13.5%,
19.4%, and 25.3%, respectively. In the moderately HF
group, mean bV70, 60 and 50 were 11%, 17.4%, and
20%, respectively. Mean penile bulb dose was 14.8 Gy
and 18 Gy for those treated with CF and moderately HF
regimens, respectively.
EBRT was completed within the planned interval in all
patients. Patients tolerated treatment well without any
acute grade 2 or higher adverse rectal or other gastrointestinal (GI) adverse events. Only 3 of 33 patients (9%)
experienced grade 1 diarrhea, one of whom was treated to
pelvic nodes. To date, no signiﬁcant late rectal toxicities
have been observed; however, the relatively short median
follow-up of 10 months (range, 3-26 months) limits such
assessment.
With respect to genitourinary outcomes, it should be
noted that 18 of 33 patients (54.5%) were on a-blockers at
baseline before hydrogel injection and radiation therapy
initiation. None of these patients required a-blocker dose
escalation. During radiation therapy, 9 of 15 patients
(60%) previously not on a-blockers were prescribed
Flomax for grade 2 acute urinary ﬂow adverse events.

Table 3

Prostate size and dosimetric outcomes

Prostate
size

Patients

Mean size
(range)

Midgland
separation

Mean rV70
(78 Gy/39
fractions)

Mean rV63
(70 Gy/28
fractions)

All patients

33

>80-100 cm3

15

>100 cm3

18

108.1 cm3
(81.1-186.6)
89 cm3
(81.1-98.3)
124 cm3
(100.1-186.6)

9.4 mm
(6.6-12.3)
9.9 mm
(6.6-19.4)
8.8 mm
(4.7-12.3)

2.25%
(0-4.7%)
2.55%
(0.73-4.7)
2%
(0-3.07)

2.33%
(0.16-6.7)
2%
(0.3-6.7)
2.56%
(0.16-5.8)
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Table 4

Dosimetric outcomes

Conventional fractionation (78 Gy/39 fractions)
Pts

rV75

rV70

rV60

rV50

All
P þ SV
P þ SV þ Lns

16
4
12

0.84% (0-2.7)
0.75% (0.06-1.77)
0.87% (0-2.7%)

2.25% (0-4.7)
2% (0.75-4.4)
2.3% (0-4.7)

5.61% (1.7-9.5)
5.47% (2.5-9.5)
5.66% (1.7-8.9)

10.5% (2.39-15.2)
10.1% (6.4-15.2)
10.7% (2.3-14.9)

P þ SV (IMRT)
P þ SV (PT)

2
2

0.58% (0.06-1.1)
0.93% (0.09-1.77)

1.61% (0.93-2.3)
2.57% (0.75-4.4)

4.95% (4.5-5.4)
6% (2.5-9.5)

9.45% (9.4-9.5)
10.8% (6.4-15.2)

Moderate hypofractionation (70 Gy/28 fractions)
All P þ SV
P þ SV (IMRT)
P þ SV (PT)

Pts

rV65

rV63

rV60

rV50

17
9
8

1.67% (0-5.8)
1.16% (0-4.6)
2.24% (0.7-5.8)

2.3% (0.1-6.7)
1.65% (0.1-5.8)
3.1% (1.3-6.7)

3.4% (0.4-9.6)
2.5% (0.3-7.8)
4.48% (2.4-9.6)

8.6% (3.3-15.7)
6.9% (2.46-15)
10.5% (4.9-15.7)

Abbreviations: IMRT Z intensity modulated radiation therapy; (P þ SV) Z prostate plus seminal vesicles; (P þ SV þ Lns) Z prostate plus seminal
vesicles plus lymph nodes; PT Z proton therapy; Pts Z patients.

Discussion
Despite improvements in prostate EBRT with widespread adoption of IMRT, radiation-induced rectal toxicity
remains a concern.8,22,23 Randomized trials using various
dose regimens show that rectal complications have not
been eliminated.24-26 Furthermore, radiation-induced rectal
toxicities remain an obstacle in dose escalation strategies.18,27
hydrogel rectal spacer is an innovation to mitigate
radiation-induced rectal toxicity.11,28
The process of transperineal percutaneous ultrasoundguided hydrogel placement is relatively simple as
described by Hatiboglu et al.12 Displacement of the
rectum with a relative reduction in rectal V70 of 60.9%
was achieved in 28 of 29 patients (96.6%).
In the study by Pinkawa et al,13 the authors report on a
learning curve with increasing hydrogel symmetry and
improved distribution through the base, middle, and apex
detected when comparing the ﬁrst 15 cases performed
with subsequent cases. Mean distance between prostate
and anterior rectal wall increased from 0.8 cm, 1.1 cm,
and 0.8 cm (ﬁrst 15 cases) at the base, middle, and apex to
1.3 cm, 1.5 cm. and 1.2 cm (subsequent cases), respectively, resulting in signiﬁcant decrease in rV70 (from 6%
vs 2%; P < .01).
Several prospective multi-institutional studies10,11 and
a number of retrospective clinical or dosimetric studies
have demonstrated the feasibility of rectal spacer application with improvement in rectal sparing.13-16,29-33
Song et al10 reported the results of a multi-institutional
study where hydrogel resulted in >7.5-mm prostate-rectal
separation in 95.8% of patients with 95.7% achieving a
reduction in rV70 of >25%. Eligibility was limited to
prostate glands <80 cm3. In the prospective randomized
phase 3 trial reported by Mariados et al,11 >97% of men

had a clinically signiﬁcant 25% relative reduction in the
rectal V70. Mean rV70 reduced from 12.4% to 3.3%
postspacer.
The dosimetric effect of rectal spacer with proton therapy planning to 78 Gy in 39 fractions was evaluated in a
study of 10 patients comparing planning CT scans before
and after spacer placement. Mean rectal V70 was signiﬁcantly reduced from 4.62% to 0.68% (P < .001).31 A
subsequent analysis of 146 patients treated with proton
therapy to 78 Gy in 39 fractions with endorectal balloon or
rectal spacer demonstrated signiﬁcant reduction in rectal
V70 favoring rectal spacer (5.7% vs 1%, P < .001).30
Our study focused on the feasibility, technical aspects,
and dosimetric outcomes of patients with large prostate
glands (>80 cm3) with a subgroup of very large glands
(>100 cm3) treated with EBRT and rectal spacer. This
study is unique in that it includes technical details with
illustrative ultrasound images of key steps used at our
institution to optimize hydrogel placement especially in
larger glands. Our experience evolved with pursuit of
midline needle placement to optimize left to right saline
and ultimately hydrogel symmetry as well as base to apex
spacer dissipation. It should be noted that the procedure is
even more meticulous in patients with large glands due to
tight rectoprostatic space (Fig 1) and requires high level
of attention to detail.
The rectal spacing achieved in our series resulted in
rV70 of 2.55% and 2% for glands measuring >80 to 100
cm3 and >100 cm3, respectively, for patients treated with
CF. When looking at the 12 patients whose treatment
included elective pelvic nodes, favorable rV70 of 2.3%
was also achieved. Similarly, within the moderate HF
group the rV63 corresponding to the 90% prescription
dose was 2% and 2.56% for glands >80 to 100 cm3 and
>100 cm3, respectively.
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Our dosimetric outcomes are in line with the results
reported by Mariados et al11 from the Pivotal trial, which
demonstrated an overall mean rV70 of 3.3% posthydrogel
injection. Of note, a secondary analysis of this trial
described a small subset of patients with prostate glands
of 80 to 100 cm3 with the postspacer rV70 of 2%, reduced
from 12% in the comparison prespacer scans.34 The authors concluded that regardless of prostatic volume, there
was consistent relative reduction in rectal V70 after spacer
placement between 70% to 84%.
Radiation exposure of the rectum and use of aspirin or
anticoagulants are correlated with increased risk of grade
2 rectal bleeding.35,36 Conceivably, patients at higher risk
for complications due to preconditions, such as use of
aspirin/anticoagulants, could beneﬁt even more from such
rectal radiation dose exposure mitigation strategies. Thus,
we consider these patients potential candidates for
hydrogel placement to maximize rectal sparing. In our
series, aspirin or anticoagulants did not preclude hydrogel
placement.
The 5-year follow-up results from the pivotal phase 3
trial conﬁrmed that the beneﬁt of rectal spacer hydrogel in
reducing the rectal dose, toxicity, and quality of life declines after image guided intensity modulated radiation
therapy was maintained or increased with a longer followup period.37 In addition, interest has emerged in evaluating the potential beneﬁts of hydrogel spacer in other
clinical outcome domains, such as sexual function.
Hamstra et al38 reported a correlation between use of
hydrogel spacer and a decrease penile bulb dose, which
was associated with improved erectile function compared
with a nonhydrogel control group based on patient-related
quality of life assessment.
The growing body of data in support of the beneﬁts of
rectal spacer led to the establishment of a new procedural
terminology code for periprostatic implantation of
hydrogel as of 2018.11,37 The newly established reimbursement rates vary depending on type of facility where
the procedure is performed. Given the variables in payment schedule coupled with the updated clinical data,
Levy et al39 sought to develop a decision-making
analytical model to evaluate the cost-effectiveness of
hydrogel spacer in radiation therapy for prostate cancer
from the perspective of the US payers. The authors proposed the development of quality-adjusted life years and
costs modeled for a 5-year period after radiation therapy,
taking into consideration the potential beneﬁts of hydrogel in various domains, such as gastrointestinal, genitourinary, and sexual function to better assist in decision
making. Finally, we believe this report builds on existing
literature and could provide useful technical guidance to
appliers who consider expanding rectal spacer utilization
in patients with large glands.
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Conclusions
In our experience, hydrogel placement is feasible in
large glands >80 cm3, even when including a subgroup of
patients with prostates >100 cm3 (100.1-186.6 cm3) with
very favorable dosimetric outcomes which are in line with
benchmark published results with smaller glands.11,34
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